20,896 results match your criteria: "University of Texas M. D. Anderson Cancer Center[Affiliation]"

Data-Driven Cutoff Selection for the Patient Health Questionnaire-9 Depression Screening Tool.

JAMA Netw Open

November 2024

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.

Article Synopsis
  • The study investigates how using small datasets to select an optimal cutoff score for the Patient Health Questionnaire-9 (PHQ-9) can lead to inaccurate results.
  • Researchers evaluated whether data-driven methods for cutoff selection resulted in scores that were significantly different from the true population optimal score and if these methods produced biased accuracy estimates.
  • Findings showed that many small studies frequently failed to identify the correct optimal cutoff score, particularly in smaller samples, leading to an overestimation of test sensitivity.
View Article and Find Full Text PDF

Cyclin D1-negative mantle cell lymphoma (MCL) is regarded as a B-cell neoplasm that has morphologic and immunophenotypic findings indistinguishable from typical MCL. These neoplasms lack cyclin D1 overexpression by immunohistochemistry and t(11;14)(q13;q32)/IGH::CCND1. Since cyclin D1-negative MCL was first recognized by gene expression profiling in 2003, there has been diagnostic confusion regarding this entity, mostly attributable to a lack of diagnostic tools to recognize these neoplasms in most clinical laboratories.

View Article and Find Full Text PDF

Background: The incidence of invasive fungal infections is increasing in immune-competent and immune-compromised patients. An examination of the recent literature related to the treatment of fungal infections was performed to address two clinical questions. First, in patients with proven or probable invasive pulmonary aspergillosis, should combination therapy with a mold-active triazole plus echinocandin be administered vs.

View Article and Find Full Text PDF

The nomenclature and classification of neuroendocrine tumors of the anterior pituitary have undergone significant change over the last few years. Despite the updated classification system as devised by the World Health Organization, some tumors do not fit neatly into the currently defined categories. The most common tumor type not defined by the updated guidelines is a pituitary neuroendocrine tumor with co-expression of SF-1 and PIT-1.

View Article and Find Full Text PDF
Article Synopsis
  • In a phase 1b study, the BCL2 inhibitor venetoclax was tested alongside a reduced chemotherapy regimen in patients with acute lymphoblastic leukemia (ALL) to determine the optimal dose while minimizing toxicity.
  • The study included 19 patients, with 90.9% of those newly diagnosed achieving complete remission and showing no deaths or serious toxicities within 60 days.
  • Results indicated that the combination therapy is well-tolerated and effective, especially in newly diagnosed patients, with a median disease-free survival of 54.6 months.
View Article and Find Full Text PDF
Article Synopsis
  • * Research is examining ways to lessen treatment intensity (de-escalation), particularly to reduce side effects from radiotherapy while maintaining effective cancer management for HPV-positive patients.
  • * Although some Phase II trials show promise for de-escalation strategies, current Phase III trials have not yet shown improved outcomes, indicating a need for more research and better risk assessment before these strategies can be routinely used outside clinical trials.
View Article and Find Full Text PDF

Background: While female survivors of Hodgkin lymphoma (HL) have an increased risk of breast cancer (BC), no BC risk prediction model is available. We developed such models incorporating mean radiation dose to the breast or breast quadrant-specific radiation doses.

Methods: Relative risks and age-specific incidence for BC and competing events (mortality or other subsequent cancer) were estimated from 1194 Dutch five-year HL survivors, treated at ages 11-40 during 1965-2000.

View Article and Find Full Text PDF

Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2-years after biologic assignment to a Donor or No Donor (SOC) Arm based on the availability of an HLA-matched sibling or unrelated donor (BMTCTN 1503; NCT02766465). A donor search was commenced after eligibility confirmation.

View Article and Find Full Text PDF
Article Synopsis
  • - The study reviews current immunotherapy approaches for small bowel neuroendocrine tumors (SBNET) and explores future avenues for better treatment responses
  • - Key treatments like somatostatin analogs and mTOR inhibitors are essential, while new applications of peptide receptor radionuclide therapy (PRRT) show promise, though existing immunotherapies have had limited success
  • - Increased incidence of SBNET highlights the need for more effective therapies, and further research into the immune microenvironment may uncover new targets for improved patient outcomes
View Article and Find Full Text PDF

Importance: The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors from the Cancer and Leukemia Group B (CALGB) 30610-Radiation Therapy Oncology Group (RTOG) 0538 trial may impact future trial design.

Objective: To assess the comprehensive demographic, disease-related, treatment-related, and social factors for potential associations with survival outcomes and understand whether specific subpopulations may benefit from radiotherapy (RT) dose escalation in LS-SCLC.

View Article and Find Full Text PDF

Therapeutic approaches to modulate the immune microenvironment in gliomas.

NPJ Precis Oncol

October 2024

Center for Neuro-Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

Article Synopsis
  • Immunomodulatory therapies, especially immune checkpoint inhibitors, have improved cancer treatment outcomes over the past decade, but gliomas show limited response to these therapies due to their complex immune microenvironment.
  • * The glioma immune microenvironment includes various cells such as macrophages, myeloid-derived suppressor cells, neutrophils, microglia, and lymphocytes, which contribute to the ineffective response to existing treatments.
  • * Recent efforts focus on understanding this unique environment and developing new therapies, including oncolytic viruses, vaccines, and cell-based therapies like CAR-T and CAR-NK cells, which are currently in clinical trials.
View Article and Find Full Text PDF

Antibiotic-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T (CAR-T) cell therapies. In this study, we observed that prior exposure to broad-spectrum ABX with extended anaerobic coverage like piperacillin-tazobactam and meropenem was associated with worsened anti-CD19 CAR-T therapy survival outcomes in large B-cell lymphoma patients (n=422), compared to other ABX classes. In a discovery subset of these patients (n=67), we found that the use of these ABX was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n=58).

View Article and Find Full Text PDF

Purpose: The topical administration of spironolactone, a mineralocorticoid receptor antagonist (MRA) improves dry eye symptoms in patients with ocular graft-versus-host disease (GVHD); however, the detailed mechanism remains unclear. This study aimed to investigate the effects of spironolactone eyedrops on the ocular surface using a chronic GVHD (cGVHD) mouse model and to determine the expression of the mineralocorticoid receptor (MR).

Methods: A cGVHD mouse model was established by allogeneic bone marrow transplantation (BMT) from B10.

View Article and Find Full Text PDF

IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.

Cell

December 2024

Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:

Article Synopsis
  • Chemotherapy combined with immune checkpoint inhibitors (ICIs) is used to boost immunotherapy effectiveness, but certain tumors, especially triple-negative breast cancer (TNBC), often remain unresponsive.
  • The study identifies IRE1α, an ER stress sensor, as a key factor that limits the immune-boosting effects of taxane chemotherapy in these tumors by silencing double-stranded RNA (dsRNA) and preventing a type of inflammatory cell death called pyroptosis.
  • Inhibiting IRE1α allows taxane to produce more dsRNA, which activates immune responses, transforming PD-L1-negative TNBC tumors into ones that are sensitive to immunotherapy.
View Article and Find Full Text PDF

Impact of Six Months of Three Different Modalities of Exercise on Stress in Post-Treatment Breast Cancer Survivors.

Cancers (Basel)

October 2024

Department of Population Health Sciences, Institute for Health Promotion Research, University of Texas Health-San Antonio, 7411 John Smith Drive, Suite 1000, San Antonio, TX 78229, USA.

Background/objectives: Extensive evidence suggests that exercise is physically and mentally beneficial for cancer survivors. This study reports on changes in self-reported stress, physiological biomarkers for stress (salivary cortisol), and HR-QOL constructs for fifty breast cancer survivors participating in one of three different exercise programs over 6 months.

Methods: Fifty post-treatment breast cancer survivors were randomized to either therapeutic yoga-based exercise (YE), comprehensive exercise (CE) (aerobic, resistance, flexibility), or choosing (C) their own exercise activities.

View Article and Find Full Text PDF

Recommended guidelines for screening for underlying malignancy in extramammary Paget's disease based on anatomic subtype.

J Am Acad Dermatol

October 2024

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address:

Article Synopsis
  • Extramammary Paget's disease (EMPD) can be linked to underlying internal adenocarcinomas, with varying associations based on the EMPD subtype.
  • A systematic literature review identified that perianal EMPD has a higher rate (25%) of associated adenocarcinomas compared to penoscrotal and vulvar types (6% each).
  • The proposed screening algorithms suggest specific tests based on EMPD subtype, emphasizing thorough screening for high-risk perianal cases and more cost-effective approaches for lower-risk penoscrotal and vulvar cases.
View Article and Find Full Text PDF

Introduction: In this study, we evaluate the association between sociodemographics and disease presentation, treatment, and survival for children, adolescents, and young adults with Ewing sarcoma.

Methods: Case-level data were downloaded from The Surveillance, Epidemiology, and End Results database. Cases included patients ages 0-24 who were diagnosed with Ewing sarcoma between 2004 and 2020.

View Article and Find Full Text PDF

Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling.

Gastroenterology

October 2024

Department of Surgery, Case Western Reserve University, Cleveland, Ohio; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio; Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Electronic address:

Article Synopsis
  • Therapy failure in metastatic colorectal cancer (mCRC), particularly in the liver, is a significant issue; new strategies are needed as existing HER3-targeting therapies have underperformed in clinical settings.
  • Research focused on how liver-derived factors, specifically leucine-rich alpha-2-glycoprotein 1 (LRG1), trigger a non-canonical HER3 activation pathway, facilitating CRC growth independent of traditional HER3 signaling.
  • Targeting the LRG1-HER3 interaction may offer novel treatment options for mCRC, showing promise for improving patient outcomes and tackling liver metastases.
View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic affected many countries and led to strict health rules that caused economic problems too.
  • Researchers studied how international flights influenced the spread of COVID-19 using a special computer model called Dynamic Weighted GraphSAGE (DWSAGE).
  • Their findings showed that areas like Western Europe, the Middle East, and North America had a big impact on the pandemic due to lots of air traffic, and they suggested ways to reduce flights to help control it.
View Article and Find Full Text PDF

Introduction: Cancer survivors experienced poorer health-related quality of life (HRQoL) and greater psychological distress during the COVID-19 pandemic than those without cancer. However, the underlying mechanisms that may explain how negative experiences during the pandemic are associated with distress and HRQoL remain unknown. We examined whether psychosocial risk factors (i.

View Article and Find Full Text PDF

In 2018, a "survival cliff" in the United States was identified among older adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). This study reassessed the cliff and associated putative causes. Survival data were obtained using the U.

View Article and Find Full Text PDF

Low-cost optical imaging technologies have the potential to reduce inequalities in healthcare by improving the detection of pre-cancer or early cancer and enabling more effective and less invasive treatment. In this Review, we summarise technologies for in vivo widefield, multi-spectral, endoscopic, and high-resolution optical imaging that could offer affordable approaches to improve cancer screening and early detection at the point-of-care. Additionally, we discuss approaches to slide-free microscopy, including confocal imaging, lightsheet microscopy, and phase modulation techniques that can reduce the infrastructure and expertise needed for definitive cancer diagnosis.

View Article and Find Full Text PDF

Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches.

Transl Oncol

December 2024

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA; Department of Gynecologic Oncology and Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, USA. Electronic address:

Article Synopsis
  • Researchers found that while a type of cancer treatment called PARP inhibitors (PARPi) works well for some ovarian cancer cells, it doesn’t work as well for others.
  • They say that combining PARPi with another drug called ATM serine/threonine kinase inhibitor (ATMi) could help treat all types of these cancer cells better.
  • This combination therapy not only kills cancer cells more effectively but also reduces some of the side effects from using PARPi alone.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the effectiveness and side effects of two chemotherapy regimens, paclitaxel and carboplatin (PC), against bleomycin, etoposide, and cisplatin (BEP) in treating newly diagnosed or recurrent ovarian sex cord-stromal tumors (SCST).
  • In a phase II trial involving 63 patients, the analysis showed that PC did not meet the criteria for being as effective as BEP, with a median progression-free survival of 27.7 months for PC compared to 19.7 months for BEP.
  • Although PC had fewer serious adverse events (77% vs. 90%), the study concluded that it failed to demonstrate non-inferiority to BE
View Article and Find Full Text PDF